News – Page 1040 – Endpoints News

Akcea, Ionis win over most FDA experts to their rare disease drug volanesorsen, vastly improving odds of success

8 years ago

China's CStone bags $260M Series B for ambitious I/O work, expanding its list of marquee investors

8 years ago

Astellas signs Asian licensing deal with Aquinox; Aravive touts early-stage PoC

8 years ago

Eight years after Eli Lilly dumped it, an upstart biotech has nabbed teplizumab and filed a $56M IPO to back a PhIII ...

8 years ago

Hunting a cure, Ex-Novartis exec Bastiano Sanna takes the reins at Cambridge diabetes startup Semma

8 years ago

Little vTv once again circles subgroup number, struggling to find something good to say about failed Alzheimer's drug

8 years ago

Playing catch-up, Eli Lilly swoops in with $1.6B cash deal for Armo Bio and its promising PhIII cancer drug

8 years ago

Roche's big PhIII Tecentriq/Cotellic combo study for colon cancer fails, damaging Exelixis shares

8 years ago

Novartis now says that it paid Trump's attorney $1.2M — and then throws ex-CEO Joe Jimenez under the bus

8 years ago

Finland's Faron hammered by surprising pivotal trial flop; CFO Simon Dingemans exits GSK in leadership makeover

8 years ago

Ironwood pleas with investors: Don't give us Alex Denner

8 years ago

Genentech allies with a metagenomics upstart in New York on a discovery deal jam packed with biobucks

8 years ago

Ex-Receptos CTO co-founds SD startup Escient, launching with $40M Series A

8 years ago

Lipocine shares tumble (again) after the FDA shows another testosterone therapy the door

8 years ago

Temasek, corporate VCs buy into prescription digital med hopes in Akili's $55M Series C

8 years ago

Evelo Bio grabs $85M as the latest early-stage biotech debuts on Nasdaq

8 years ago

Stormy Daniels’ lawyer: Novartis made $400K in 'suspicious' payments to Trump attorney Michael Cohen

8 years ago

Can you cut $600M in R&D costs without slash-and-burn tactics? Andy Plump aims to show us how

8 years ago

Daiichi scores in PhIII study of AML drug, beating chemo and building its case for worldwide approvals

8 years ago

Atara enlists Juno co-founder Michel Sadelain in CAR-T effort; Valeant no more, Bausch is the new marquee name

8 years ago

Listing in Shanghai, WuXi AppTec raises a $354M IPO for China R&D facilities

8 years ago

Ionis, Akcea team face some tough questions on safety as FDA insiders ponder risks linked to volanesorsen

8 years ago

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer's

8 years ago

The (new) top 10 pharma companies by 2017 revenue

8 years ago

First page Previous page 1037 1038 103910401041 1042 1043 Next page Last page